SciSparc (SPRC) Total Liabilities (2016 - 2025)
SciSparc (SPRC) posted Total Liabilities of $2.5 million for Q4 2025, down 51.84% sequentially from $5.1 million in Q2 2025, and up 75.78% YoY from $1.4 million in Q4 2024.
SciSparc (SPRC) Total Liabilities (2016 - 2025) Analysis & Trends
SciSparc has reported Total Liabilities for 10 years, with the latest figure at $2.5 million in Q4 2025.
- Quarterly Total Liabilities rose 75.78% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 75.78% YoY) and the FY2025 annual result came in at $2.5 million, up 75.78% from the prior year.
- Total Liabilities slipped to $2.5 million in Q4 2025 per SPRC's latest filing, from $5.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $14.4 million in Q2 2022 and troughed at $1.4 million in Q4 2024.
- A 5-year average of $8.1 million and a median of $9.9 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2024: Total Liabilities surged 423.67% in 2021, then slumped 87.41% in 2024.
- Over 5 years, Total Liabilities stood at $9.9 million in 2021, then grew by 6.95% to $10.6 million in 2022, then climbed by 5.44% to $11.2 million in 2023, then sank by 87.41% to $1.4 million in 2024, then soared by 75.78% to $2.5 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.5 million, $5.1 million, and $1.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 10.03 Bn |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | 2.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.48 Mn |
| Jun 30, 2025 | 5.14 Mn |
| Dec 31, 2024 | 1.41 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Dec 31, 2023 | 11.18 Mn |
| Jun 30, 2023 | 9.89 Mn |
| Dec 31, 2022 | 10.61 Mn |
| Sep 30, 2022 | 5.76 Mn |
| Jun 30, 2022 | 14.42 Mn |
| Dec 31, 2021 | 9.92 Mn |
| Jun 30, 2021 | 8.34 Mn |
| Dec 31, 2020 | 2.56 Mn |
| Jun 30, 2020 | 1.59 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Jun 30, 2019 | 2.08 Mn |
| Mar 31, 2019 | 5.42 Mn |
| Dec 31, 2018 | 4.56 Mn |
| Jun 30, 2018 | 6.39 Mn |
| Mar 31, 2018 | 8.06 Mn |
| Dec 31, 2017 | 9.57 Mn |